Increased use of high tech medical devices entail significant institutional costs in terms of capital and processing for reuse. The sterilization of these devices plays a significant role in providing patient care in a manner to prevent patient morbidity and even mortality. Critical medical devices that are heat- and moisture- sensitive require low-temperature sterilization. This research supports the development of a significantly more efficient low-temperature gas plasma sterilizer (GPS). Unlike currently available low-temperature gas plasma sterilizers, the Phygen system relies on the discharge plasma field, rather than chemical vapor (i.e. H2O2), for sterilization activity. The GPS does not require any facility renovation for installation or operation. Preliminary studies have demonstrated the ability of the GPS to sterilize lumens of test units having significantly smaller diameters of longer lengths than currently available gas plasma systems which are limited to Stainless steel devices of 3mm ID lumens 40 cm in length and in non-stainless steel devices to 6ram ID lumens 31 cm in length. Milestones to be completed at the end of Phase I research are identification of numerous surface geometries and materials for which sporicidal inactivation can be achieved using a cycle time of equal to or less than 60 minutes and characterization of the discharge plasma field. The GPS will positively impact healthcare providers, healthcare consumers, and medical device manufacturers. The GPS will reduce the device turnaround time for reprocessing centers, reduce device inventories, and potentially reduce the morbidity and mortality from nosocomial infection. This sterilizer may also provide medical device manufacturers greater flexibility in device design, allowing more use of heat and moisture-sensitive materials and less restrictive device configurations, and lessen their dependence on off-site sterilization vendors. The GPS represents a true gas plasma technology with the ability to sterilize critical medical devices without the toxicities associated with surface residuals or atmospheric emissions. This sterilization method can provide a faster, more reliable, and more economical sterilizer. Sterilization by this methodology may further assist in the clinical management of newly discovered infectious agents, such as prions.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Small Business Innovation Research Grants (SBIR) - Phase I (R43)
Project #
1R43HL074653-01A1
Application #
6789142
Study Section
Special Emphasis Panel (ZRG1-SSS-8 (10))
Program Officer
Mitchell, Phyllis
Project Start
2004-05-01
Project End
2004-10-31
Budget Start
2004-05-01
Budget End
2004-10-31
Support Year
1
Fiscal Year
2004
Total Cost
$134,984
Indirect Cost
Name
Sterilucent, Inc.
Department
Type
DUNS #
005634969
City
Minneapolis
State
MN
Country
United States
Zip Code
55413